Cardiovascular complications following COVID-19 immunization differ across vaccine platforms and dosing schedules, with mRNA vaccines showing distinct patterns of myocarditis and pericarditis compared to vector-based or inactivated options.
The claim is specific, empirical, and testable. Retrieved studies such as [3] and [4] explicitly compare cardiovascular complications (like myocarditis and thrombotic events) across different vaccine types (mRNA vs vector-based) and vaccination statuses (such as prime vs. booster doses). All relevant source papers that investigate vaccine-specific cardiovascular outcomes support the assertion that these complication rates vary by vaccine type and status.